DeepMed Research

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study to Learn How a Tablet Compared With an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up Into the Blood in Healthy Adults

Phase 1

Recruiting

Conditions: Healthy Participants

Interventions: Drug: Vepdegestrant (Reference)
Drug: Vepdegestrant (Test)

First Posted Date: 2025-04-04

Last Posted Date: 2025-05-11

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT06911788

Locations: 🇳🇱
ICON, Groningen, Netherlands
🇳🇱
ICON - screening centre, Utrecht, Netherlands

A Study to Learn if the Study Medicine Called Carbamazepine Changes How the Body Processes PF-07220060

Phase 1

Not yet recruiting

Conditions: Healthy Adults

Interventions: Drug: PF-07220060
Drug: Carbamazepine ER Tablet

First Posted Date: 2025-03-27

Last Posted Date: 2025-03-27

Lead Sponsor: Pfizer

Target Recruit Count: 14

Registration Number: NCT06897683

Locations: 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States

Consistency of Response With Rimegepant in Acute Treatment of Migraine

Not yet recruiting

Conditions: Migraine

Interventions: Drug: Rimegepant for acute migraine treatment

First Posted Date: 2025-03-27

Last Posted Date: 2025-04-10

Lead Sponsor: Pfizer

Target Recruit Count: 250

Registration Number: NCT06898047

Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

Not yet recruiting

Conditions: Atopic Dermatitis
Atopic Dermatitis, Unspecified
Dermatitis, Atopic

Interventions: Drug: Abrocitinib

First Posted Date: 2025-03-27

Last Posted Date: 2025-05-13

Lead Sponsor: Pfizer

Target Recruit Count: 150

Registration Number: NCT06899204

A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults

Phase 3

Active, not recruiting

Conditions: Respiratory Syncytial Virus (RSV)

Interventions: Biological: RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE
Biological: HZ/su VACCINE

First Posted Date: 2025-03-24

Last Posted Date: 2025-05-13

Lead Sponsor: Pfizer

Target Recruit Count: 525

Registration Number: NCT06890416

Locations: 🇵🇷
Clinical Research Puerto Rico, San Juan, Puerto Rico
🇺🇸
DelRicht Research, New Orleans, Louisiana, United States
🇺🇸
Clinical Neuroscience Solutions Inc., Memphis, Tennessee, United States

and more 22 locations

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

Phase 3

Recruiting

Conditions: Alopecia Areata

Interventions: Drug: Ritlecitinib 100 mg
Drug: Ritlecitinib 50 mg
Drug: Placebo - 50 mg
Drug: Placebo - 100 mg

First Posted Date: 2025-03-13

Last Posted Date: 2025-05-08

Lead Sponsor: Pfizer

Target Recruit Count: 550

Registration Number: NCT06873945

Locations: 🇺🇸
Burke Pharmaceutical Research, Hot Springs, Arkansas, United States
🇺🇸
Southern California Clinical Research, Santa Ana, California, United States
🇺🇸
Brett King MD, LLC, Fairfield, Connecticut, United States

and more 17 locations

A Study to Learn More About Tukysa Once it is Out in the Korean Market

Not yet recruiting

Conditions: HER2-positive Locally Advanced Unresectable
Metastatic Breast Cancer

First Posted Date: 2025-03-12

Last Posted Date: 2025-03-12

Lead Sponsor: Pfizer

Target Recruit Count: 600

Registration Number: NCT06873191

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers.

Phase 1

Recruiting

Conditions: Peripheral T Cell Lymphoma
Diffuse Large B-cell Lymphoma
Classical Hodgkin Lymphoma
Head and Neck Squamous Cell Carcinoma
Melanoma
Non-Small Cell Lung Cancer

Interventions: Drug: PF-08046032
Drug: Sasanlimab

First Posted Date: 2025-03-11

Last Posted Date: 2025-05-20

Lead Sponsor: Pfizer

Target Recruit Count: 220

Registration Number: NCT06870487

Locations: 🇺🇸
Fred Hutchinson Cancer Center., Seattle, Washington, United States
🇺🇸
University of Washington Medical Center- Montlake, Seattle, Washington, United States
🇺🇸
NEXT Oncology, San Antonio, Texas, United States

A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose

Phase 3

Recruiting

Conditions: RSV Infection

Interventions: Biological: RSVpreF
Biological: Placebo

First Posted Date: 2025-03-10

Last Posted Date: 2025-05-02

Lead Sponsor: Pfizer

Target Recruit Count: 550

Registration Number: NCT06866405

Locations: 🇺🇸
Advanced Specialty Research, Boise, Idaho, United States
🇺🇸
Saint Alphonsus Regional Medical Center, Boise, Idaho, United States
🇺🇸
Velocity Clinical Research - New Orleans, New Orleans, Louisiana, United States

and more 20 locations

A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan

Not yet recruiting

Conditions: Infectious Diseases

Interventions: Drug: Avibactam sodium/Ceftazidime hydrate

First Posted Date: 2025-03-07

Last Posted Date: 2025-05-13

Lead Sponsor: Pfizer

Target Recruit Count: 59

Registration Number: NCT06864585

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy